PG
SGMO

PEAK6 Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

PEAK6 Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,350
Closed -$20K – 4718
2017
Q3 		$20K Buy
+1,350
New +$14.9K ﹤0.01% 4176

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PEAK6 Group's SGMO Position: Q4 2017 in Review

PEAK6 Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2017, closing a stake of 1,350 shares — an estimated $20K sold.

PEAK6 Group first reported a position in SGMO in Q3 2017 and held it in 1 quarter. The position peaked at $20K in Q3 2017. 170 funds tracked by Wall St. Rank hold SGMO as of Q4 2017.

  • PEAK6 Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2017 after selling out during the quarter.
  • PEAK6 Group sold 1,350 SANGAMO THERAPEUTICS INC shares in Q4 2017, an estimated $20K.
  • PEAK6 Group first reported a position in SANGAMO THERAPEUTICS INC in Q3 2017 and held it in 1 quarter.
  • PEAK6 Group's SANGAMO THERAPEUTICS INC position peaked at $20K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2017.

Based on PEAK6 Group's 13F filing for Q4 2017, filed 14 Feb 2018.